Multimodal Biomarkers for Diagnosis and Prognosis in CAA
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
By combination of plasma (Aβ40, Aβ42, total tau, and phosphorylated tau, etc.), genetic (ApoE
ε2 or ε4 allele), MRI (cerebral perfusion, microbleeds, cortical superficial siderosis,
enlarged perivascular space, etc.) and PET imaging (amyloid and tau) biomarkers, the study
aims to
1. Enhance the diagnostic potentials of the radiological biomarkers by combining MRI and
amyloid PET in CAA patients.
2. Investigate the biological pathogenesis in CAA patients using the less invasive plasma
biomarkers and to correlate with structural and function imaging, including MRI, amyloid
and tau imaging.
3. Study the characteristics of long-term progression of amyloid deposition in CAA patients
using the radiological, biochemical and genetic biomarkers.
4. Study the prognosis predicting markers.